One of the most common questions about ibutamoren is whether it "shuts down" your own testosterone the way anabolic steroids and SARMs do, and does it require any kind of "recovery therapy" afterwards. The answer requires an understanding of two different hormonal axes. The editors explain what is known from physiology and research, and where gaps remain.
Two hormonal axes: why it matters
Testosterone production in men is regulated by the "hypothalamus-pituitary-gonadal" axis. The hypothalamus releases in pulses gonadotropin-releasing hormone (GnRH), in response, the pituitary gland secretes luteinizing (LH) and follicle-stimulating (FSH) hormones, and LH stimulates the Leydig cells in the testicles to synthesize testosterone. When there is a lot of testosterone or estradiol, they inhibit the hypothalamus and pituitary gland - this is a negative feedback.
Ibutamoren works in a different system — the "growth hormone — IGF-1" axis. Here, the hypothalamus secretes growth hormone-releasing hormone and somatostatin, the pituitary gland produces growth hormone, and the liver in response synthesizes IGF-1. The target of ibutamoren is the ghrelin receptor GHSR-1a, which specifically enhances somatotropic secretion.
These two axes are not completely isolated: both are controlled by the hypothalamus and pituitary gland, and the hormones of one can influence the other. However, the main thing for our question is that ibutamoren is not an androgen and does not send the signal "testosterone is enough" to the brain.
It is through this signal that anabolic steroids and SARMs suppress their own testosterone production. Exogenous androgen binds to androgen receptors in the hypothalamus and pituitary gland, and they reduce the secretion of LH and FSH. Ibutamoren does not have this mechanism.
Why ibutamoren does not work as a steroid
Ibutamoren does not bind to androgen or estrogen receptors and is not converted in the body to sex steroids. It only enhances the release of its own growth hormone, which is not a direct regulator of LH secretion.
Because of this, the classic “axis suppression” scenario familiar to steroid users—testicular atrophy, LH and FSH dropping to near-zero values, spermatogenesis arrest—is not expected for pure ibutamoren. An Endocrine Society review (Pope et al., 2014) describes this type of suppression specifically as a consequence of androgens.
| Parameter | Anabolic steroids | SARM | Ibutamoren |
|---|---|---|---|
| Target | Androgen receptor | Androgen receptor (selective) | Ghrelin receptor GHSR-1a |
| Direct LH/FSH feedback signal | Yes, pronounced | Yes, dose-dependent | No |
| Typical testosterone suppression | Pronounced | Described in research | Not described as a typical effect |
| Effect on prolactin and cortisol | Indirect | Little data | Moderate, mostly temporary increase |
In comparison, in studies of SARMs such as LGD-4033 (ligandrol), even low doses dose-dependently decreased total testosterone. There are no similar data in the literature for ibutamoren, and this logically follows from the mechanism.
At the same time, "does not suppress directly" does not mean "no effect". There are several indirect pathways through which a substance could theoretically alter reproductive function, and these are worth considering separately.
Indirect ways of influence on the gonads
Prolactin. Ghrelin receptor agonists can increase prolactin levels. High prolactin is known as a cause of secondary hypogonadism: it suppresses the pulsatile secretion of GnRH. However, in the ibutamoren studies, prolactin elevations were modest and resolved over time, so clinically significant hyperprolactinemia is not an expected scenario. However, the situation may be different in people with initially high prolactin.
Cortisol. Ghrelin and its mimetics stimulate the stress axis by increasing ACTH and cortisol. Prolonged high cortisol can suppress the gonadal axis. As with prolactin, in studies this effect was moderate and diminished with long-term use.
Ghrelin itself. Physiological studies show that ghrelin can have a central inhibitory effect on the gonadal axis. In particular, in the work of Lanfranco et al. (2008), administration of acylated ghrelin to young men suppressed spontaneous LH pulsation. Whether ibutamoren reproduces this effect to a clinically significant extent with long-term use is unknown.
Metabolic changes. Obesity and insulin resistance are themselves associated with lower testosterone in men. Since ibutamoren increases appetite and impairs insulin sensitivity, such an indirect effect is theoretically possible with long-term use.
What the research says
Clinical trials of ibutamoren focused on growth hormone, IGF-1, body composition, and carbohydrate metabolism. There are few systematic data on LH, FSH, testosterone and spermatogenesis in published works. In the literature available to us, we found no reports of clinically significant testosterone suppression as a characteristic side effect.
It is important to understand that the absence of a signal in studies that were not designed to look for it is not the same as a proven lack of effect. Most of the participants were elderly, for whom baseline testosterone is often low.
Instead, in real uncontrolled use, ibutamoren is often combined with steroids or SARMs. In this case, inhibition of the axis is expected, but it is caused by androgens. It is wrong to attribute it to ibutamoren, as well as to think that ibutamoren is able to "compensate" for this suppression.
Another pitfall is the unknown composition of products. Independent tests of drugs marketed as "research chemicals" have found undeclared substances in them, including SARMs. If testosterone suddenly dropped during "pure" ibutamoren, you should also think about this option.
- There is no direct mechanism of inhibition, as in androgens.
- Indirect pathways (prolactin, cortisol, ghrelin action, metabolism) are theoretically possible.
- There is little reliable clinical data on testosterone on the background of ibutamoren.
- Suppression when combined with androgens is due to androgens themselves.
How to assess your own hormonal status
If a person has symptoms that may indicate low testosterone—decrease in libido, erectile dysfunction, fatigue, mood swings—the first step should be to consult an endocrinologist or andrologist, not to make independent conclusions.
Endocrine Society clinical guidelines (Bhasin et al., 2018) recommend measuring total testosterone in the morning on an empty stomach and confirming a low value with a repeat analysis. Assessment of LH and FSH helps to understand exactly where the problem is: in the testicles or at the level of the hypothalamus and pituitary gland.
If you are taking any unregistered substances, it is important to honestly inform your doctor about it. The interpretation of the tests depends on this: prolactin, cortisol, glucose and IGF-1 can be changed precisely because of ibutamoren.
Self-prescribing "restorative" drugs without a diagnosis makes no sense and carries risks. The decision on any treatment is made by the doctor based on the examination.
Editorial conclusions
Ibutamoren does not have a direct mechanism of testosterone suppression, characteristic of anabolic steroids and SARMs, because it does not act on androgen receptors.
However, there are theoretical indirect ways of influence — through prolactin, cortisol, central action of ghrelin, and metabolic changes. Their clinical significance has not been established, and there are few targeted studies.
If testosterone drops with multiple substances, the culprits are often androgens or a poor quality product, but a clinician must assess the full picture rather than assume the cause.
We also advise you to read our materials on the side effects of ibutamoren, on the counterfeiting of this substance on the market, and on tests to control the hormonal background.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601–611.
- Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249–4257.
- Lanfranco F, Bonelli L, Baldi M, et al. Acylated ghrelin inhibits spontaneous luteinizing hormone pulsatility and responsiveness to naloxone but not that to gonadotropin-releasing hormone in young men: evidence for a central inhibitory action of ghrelin on the gonadal axis. J Clin Endocrinol Metab. 2008;93(9):3633–3639.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004–2010.
